RAS proteins are binary switches that cycle between active GTP-bound and inactive GDP-bound states, playing a crucial role in signal transduction. Mutations in RAS genes or their regulators can lead to persistent activation, contributing to diseases like cancer, RASopathies, and psychiatric disorders. RAS proteins interact with membranes, and their activity is regulated by GEFs and GAPs, which control GTP/GDP exchange. The switch mechanism involves conformational changes in switch regions, with GEFs promoting GTP binding and GAPs facilitating GTP hydrolysis. RAS proteins activate effectors by recruiting them to the plasma membrane, and their activity is influenced by membrane composition and lipid interactions. RAS effectors include RAF kinases, PI3K, RalGDS, and others, with distinct roles in signaling pathways. RAS proteins are also involved in membrane trafficking and localization, with different isoforms interacting with specific lipids and membrane domains. RASopathies, such as neurofibromatosis type 1 and Noonan syndrome, are caused by mutations in RAS pathway genes, leading to hyperactivation of the RAS/MAPK pathway. RAS proteins can form dimers or higher-order structures, which may influence signaling. RAS mutations are common in cancer, with mutations in KRAS, NRAS, and HRAS being prevalent. RASopathies are associated with a range of clinical features, including neurofibromas, cardiovascular issues, and developmental abnormalities. Therapeutic approaches targeting RAS include inhibitors of upstream signaling and direct targeting of RAS proteins, though effective treatments remain challenging due to the complex regulation of RAS activity.RAS proteins are binary switches that cycle between active GTP-bound and inactive GDP-bound states, playing a crucial role in signal transduction. Mutations in RAS genes or their regulators can lead to persistent activation, contributing to diseases like cancer, RASopathies, and psychiatric disorders. RAS proteins interact with membranes, and their activity is regulated by GEFs and GAPs, which control GTP/GDP exchange. The switch mechanism involves conformational changes in switch regions, with GEFs promoting GTP binding and GAPs facilitating GTP hydrolysis. RAS proteins activate effectors by recruiting them to the plasma membrane, and their activity is influenced by membrane composition and lipid interactions. RAS effectors include RAF kinases, PI3K, RalGDS, and others, with distinct roles in signaling pathways. RAS proteins are also involved in membrane trafficking and localization, with different isoforms interacting with specific lipids and membrane domains. RASopathies, such as neurofibromatosis type 1 and Noonan syndrome, are caused by mutations in RAS pathway genes, leading to hyperactivation of the RAS/MAPK pathway. RAS proteins can form dimers or higher-order structures, which may influence signaling. RAS mutations are common in cancer, with mutations in KRAS, NRAS, and HRAS being prevalent. RASopathies are associated with a range of clinical features, including neurofibromas, cardiovascular issues, and developmental abnormalities. Therapeutic approaches targeting RAS include inhibitors of upstream signaling and direct targeting of RAS proteins, though effective treatments remain challenging due to the complex regulation of RAS activity.